Your browser doesn't support javascript.
loading
Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.
Erlmeier, Maximilian; Mikuteit, Marie; Zschäbitz, Stefanie; Autenrieth, Michael; Weichert, Wilko; Hartmann, Arndt; Steffens, Sandra; Erlmeier, Franziska.
Afiliação
  • Erlmeier M; Department of Urology, München Klinik Bogenhausen, Munich, Germany.
  • Mikuteit M; Department for Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany. Mikuteit.marie@mh-hannover.de.
  • Zschäbitz S; Dept. of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Autenrieth M; Department of Urology, Technical University of Munich, Klinikum Rechts der Isar, München, Germany.
  • Weichert W; Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
  • Hartmann A; Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
  • Steffens S; Department for Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
  • Erlmeier F; Department of Urology, University Hospital Münster, Münster, Germany.
BMC Urol ; 23(1): 90, 2023 May 11.
Article em En | MEDLINE | ID: mdl-37170275
ABSTRACT

BACKGROUND:

The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC).

METHODS:

Patients who underwent renal surgery due to chRCC were recruited. Clinical data was retrospectively evaluated. Tumor specimen were analyzed for HGF expression by immunohistochemistry.

RESULTS:

81 chRCC patients were eligible for analysis, thereof 37 (45.7%) patients were positive for HGF. No significant associations were found for HGF expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in 5-year overall survival (OS) for patients with HGF- compared to HGF+ tumors (95.0% versus 90.9%; p = 0.410).

CONCLUSIONS:

In chRCC HGF expression is not associated with parameters of aggressiveness or survival.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article